Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GPCR NASDAQ:LENZ NASDAQ:TVRD NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPCRStructure Therapeutics$20.91+0.1%$18.90$13.22▼$45.37$1.20B-1.881.03 million shs1.47 million shsLENZLENZ Therapeutics$41.33+1.3%$35.89$16.53▼$42.77$1.16B0.45478,020 shs348,109 shsTVRDTvardi Therapeutics$33.88-4.3%$26.83$8.13▼$36.71$331.96M0.2520,093 shs39,705 shsZYMEZymeworks$15.74-3.6%$13.92$9.03▼$17.70$1.23B1.27527,939 shs336,972 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPCRStructure Therapeutics0.00%-5.30%+12.84%-3.55%-47.25%LENZLENZ Therapeutics0.00%-1.55%+1.03%+42.52%+95.69%TVRDTvardi Therapeutics0.00%+8.90%+42.41%+37.61%+3,387,999,900.00%ZYMEZymeworks0.00%+4.58%+10.07%+24.23%+30.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPCRStructure Therapeutics$20.91+0.1%$18.90$13.22▼$45.37$1.20B-1.881.03 million shs1.47 million shsLENZLENZ Therapeutics$41.33+1.3%$35.89$16.53▼$42.77$1.16B0.45478,020 shs348,109 shsTVRDTvardi Therapeutics$33.88-4.3%$26.83$8.13▼$36.71$331.96M0.2520,093 shs39,705 shsZYMEZymeworks$15.74-3.6%$13.92$9.03▼$17.70$1.23B1.27527,939 shs336,972 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPCRStructure Therapeutics0.00%-5.30%+12.84%-3.55%-47.25%LENZLENZ Therapeutics0.00%-1.55%+1.03%+42.52%+95.69%TVRDTvardi Therapeutics0.00%+8.90%+42.41%+37.61%+3,387,999,900.00%ZYMEZymeworks0.00%+4.58%+10.07%+24.23%+30.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGPCRStructure Therapeutics 3.11Buy$75.71262.10% UpsideLENZLENZ Therapeutics 3.00Buy$49.6020.01% UpsideTVRDTvardi Therapeutics 3.00Buy$64.2589.64% UpsideZYMEZymeworks 2.90Moderate Buy$21.4336.14% UpsideCurrent Analyst Ratings BreakdownLatest TVRD, LENZ, GPCR, and ZYME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025GPCRStructure TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $22.008/7/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $60.008/7/2025GPCRStructure TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$92.00 ➝ $90.008/7/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$89.00 ➝ $87.007/31/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.00 ➝ $49.007/31/2025LENZLENZ TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$39.00 ➝ $40.007/28/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $48.007/14/2025TVRDTvardi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$62.007/11/2025TVRDTvardi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$52.007/3/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$13.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/ALENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/ATVRDTvardi TherapeuticsN/AN/AN/AN/A($3.02) per shareN/AZYMEZymeworks$122.87M9.63N/AN/A$6.63 per share2.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGPCRStructure Therapeutics-$122.53M-$1.05N/AN/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%11/5/2025 (Estimated)TVRDTvardi Therapeutics-$70.87MN/A0.00∞N/A-678.79%-565.83%-66.71%N/AZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest TVRD, LENZ, GPCR, and ZYME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TVRDTvardi Therapeutics-$0.51-$1.00-$0.49-$1.00N/AN/A8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 million8/6/2025Q2 2025GPCRStructure Therapeutics-$0.28-$0.36-$0.08-$0.36N/AN/A7/30/2025Q2 2025LENZLENZ Therapeutics-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGPCRStructure TherapeuticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGPCRStructure TherapeuticsN/A20.4820.48LENZLENZ TherapeuticsN/A20.5420.54TVRDTvardi TherapeuticsN/A4.044.04ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGPCRStructure Therapeutics91.78%LENZLENZ Therapeutics54.32%TVRDTvardi Therapeutics44.66%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipGPCRStructure Therapeutics5.60%LENZLENZ Therapeutics6.90%TVRDTvardi Therapeutics3.10%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGPCRStructure Therapeutics13657.60 million54.37 millionOptionableLENZLENZ Therapeutics11028.52 million26.55 millionN/ATVRDTvardi Therapeutics809.38 million9.09 millionN/AZYMEZymeworks46075.17 million67.56 millionOptionableTVRD, LENZ, GPCR, and ZYME HeadlinesRecent News About These CompaniesBrokers Set Expectations for Zymeworks FY2025 EarningsSeptember 7, 2025 | marketbeat.comEcoR1 Capital LLC Purchases 2,231,469 Shares of Zymeworks Inc. $ZYMESeptember 6, 2025 | marketbeat.comTrexquant Investment LP Has $2.63 Million Stake in Zymeworks Inc. $ZYMESeptember 6, 2025 | marketbeat.comBloom Burton Comments on Zymeworks FY2025 EarningsSeptember 6, 2025 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 5, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - What's Next?September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires New Position in Zymeworks Inc. $ZYMESeptember 4, 2025 | marketbeat.comZymeworks Inc. $ZYME Stake Reduced by Redmile Group LLCSeptember 4, 2025 | marketbeat.comZymeworks Inc. $ZYME Shares Acquired by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comHealth Sector Innovations: From Blood Thinners to Bird Flu OutbreaksSeptember 3, 2025 | devdiscourse.comDZymeworks: Despite T-Cell Engager Setback, ADC Candidates Press OnSeptember 2, 2025 | seekingalpha.comZymeworks drops clinical-stage T-cell engager after assessing benefit-risk profileSeptember 2, 2025 | fiercebiotech.comFZymeworks halts development of cancer drug after trial setbackSeptember 2, 2025 | reuters.comZymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell EngagerSeptember 2, 2025 | globenewswire.comWellington Management Group LLP Reduces Stock Holdings in Zymeworks Inc. $ZYMESeptember 2, 2025 | marketbeat.comNuveen LLC Acquires Shares of 198,812 Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comVanguard Group Inc. Decreases Stock Position in Zymeworks Inc. $ZYMESeptember 1, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Zymeworks Inc. $ZYMEAugust 31, 2025 | marketbeat.comWalleye Capital LLC Has $2.95 Million Stake in Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comAlphaQuest LLC Purchases 28,868 Shares of Zymeworks Inc. $ZYMEAugust 30, 2025 | marketbeat.comZymeworks Reports Q2 Results and FDA ClearanceAugust 19, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVRD, LENZ, GPCR, and ZYME Company DescriptionsStructure Therapeutics NASDAQ:GPCR$20.91 +0.03 (+0.14%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$21.16 +0.25 (+1.22%) As of 09/12/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.LENZ Therapeutics NASDAQ:LENZ$41.33 +0.52 (+1.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$41.02 -0.31 (-0.74%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Tvardi Therapeutics NASDAQ:TVRD$33.88 -1.52 (-4.29%) As of 09/12/2025 04:00 PM EasternCara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Zymeworks NYSE:ZYME$15.74 -0.58 (-3.55%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$15.98 +0.23 (+1.49%) As of 09/12/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
